HEALTH ECONOMICS & REIMBURSEMENT

Amplatzer Piccolo™ Occluder Coding and Reimbursement Guide

The following codes describe the implantation of the Amplatzer Piccolo™ Occluder for Patent Ductus Arteriosus (PDA) closure.

For questions regarding billing and reimbursement of the Amplatzer Piccolo™ Occluder, please contact the Abbott reimbursement team on the reimbursement hotline at (855) 569-6430 or hce@abbott.com.

COVERAGE CONSIDERATIONS FOR DEVICES INTENDED FOR PREMATURE INFANTS

The Amplatzer Piccolo™ Occluder is intended for very small infants; as a result, it is likely that pediatric patients will have private payer coverage or Medicaid. In some cases, these patients may have no insurance coverage. While it is not likely that these patients will be Medicare beneficiaries, we refer to Medicare payment rates in this guide as baseline or payment references for providers.

PRIVATE PAYER COVERAGE

Most private payers currently cover percutaneous PDA closure with the Amplatzer Duct Occluder II. Check with your private payers for specific coverage policies regarding the Amplatzer Piccolo™ Occluder. Prior authorization is recommended if possible.

MEDICAID COVERAGE

Babies who are born premature often may qualify for Supplemental Security Income (SSI) and Medicaid. Qualification for SSI is based on the child's birth weight and/or gestational age as well as family income and assets. (Weight requirements: a child who weighs less than 2 pounds 10 ounces, at birth or no more than 4 pounds, 6 ounces, at birth but is considered small for his or her gestational age).

In many states, a baby who receives SSI benefits maybe automatically eligible for Medicaid to help pay for health care costs. Parents may be able to apply for SSI benefits for their child at a local Social Security Administration office or be directed to the office where they can apply for Medicaid.[1]

PHYSICIAN SERVICES [2]

Medicare national average physician payment level for CPT‡ code 93582 is **$632** for Calendar Year 2024. While premature infants are rarely Medicare beneficiaries, the Medicare rate may serve as a baseline amount for physician payment. Private payer and Medicaid rates may vary substantially, from Medicare rates; however, differentials from Medicare rates are usually consistent across procedures.

CPT‡ Code	Description
93582	Percutaneous transcatheter closure of patent ductus arteriosus

HOSPITAL SERVICES [3]

Patients are likely to receive the Amplatzer Piccolo™ Occluder during their initial inpatient stay after being born. Due to the high incidence of multiple comorbidities for these premature infants, the inpatient stay is likely to be lengthy with a significant portion of the stay in the neonatal intensive care unit (NICU). When the hospital is reimbursed under a prospective payment system, such as MS-DRGs or a negotiated per-diem rate, it is unlikely that the implant of the Amplatzer Piccolo™ Occluder will be reimbursed with a separate payment. The overall reimbursement for the inpatient stay is likely to include a single payment for all services delivered during the stay.

ICD-10-PCS Code	Description
02LR3DT	Occlusion of ductus arteriosus with intraluminal device, percutaneous

Payment for an isolated PDA closure is unlikely but might occur in some scenarios. Medicare payment for an isolated PDA closure can serve a baseline or payment reference amount. However, payment by Medicare is unlikely due to the premature infant patient population for which the Amplatzer Piccolo™ Occluder is indicated. The Medicare rate for PDA closure is determined by the MS-DRG assigned for the procedure. PDA closures are assigned MS-DRG 270, 271 or 272 (Other Major Cardiovascular Procedures w/MCC, w/CC, or w/o CC/MCC) that have respective Medicare national payment rates of **$35,406, $24,199 , and $17,080** in fiscal year 2023, effective Oct 1, 2023, to Sept 30, 2024.

Rx Only

Important Safety Information

AMPLATZER PICCOLO™ OCCLUDER

Indication Of Use
The Amplatzer Piccolo™ Occluder is a percutaneous, transcatheter occlusion device intended for the nonsurgical closure of a patent ductus arteriosus (PDA).

Contraindications
Weight < 700 grams at time of the procedure; Age < 3 days at time of procedure; Coarctation of the aorta; Left pulmonary artery stenosis; Cardiac output that is dependent on right to left shunt through the PDA due to pulmonary hypertension; Intracardiac thrombus that may interfere with the implant procedure; Active infection requiring treatment at the time of implant; Patients with a PDA length smaller than 3 mm; Patients with a PDA diameter that is greater than 4 mm at the narrowest portion.

Potential Adverse Events
Potential adverse events that may occur during or after a procedure using this device may include, but are not limited to: Air embolus, Allergic reaction, Anemia, Anesthesia reactions, Apnea, Arrhythmia, Bleeding, Cardiac perforation, Cardiac tamponade, Chest pain, Device embolization, Device erosion, Death, Endocarditis, Fever, Headache/migraine, Hemolysis, Hematoma, Hypertension, Hypotension, Infection, Myocardial infarction, Palpitations, Partial obstruction of aorta, Partial obstruction of pulmonary artery, Pericardial effusion, Pericarditis, Peripheral embolism, Pleural effusion, Pulmonary embolism, Re-intervention for device removal, Respiratory distress, Stroke, Thrombus, Transient ischemic attack, Valvular regurgitation, Vascular access site injury, Vascular occlusion, Vessel perforation.

Disclaimer
This material and the information contained herein is for general information purposes only and is not intended, and does not constitute, legal, reimbursement, business, clinical, or other advice. Furthermore, it is not intended to and does not constitute a representation or guarantee of reimbursement, payment, or charge, or that reimbursement or other payment will be received. It is not intended to increase or maximize payment by any payer. Abbott makes no express or implied warranty or guarantee that the list of codes and narratives in this document is complete or error-free. Similarly, nothing in this document should be viewed as instructions for selecting any particular code, and Abbott does not advocate or warrant the appropriateness of the use of any particular code. The ultimate responsibility for coding and obtaining payment/reimbursement remains with the customer. This includes the responsibility for accuracy and veracity of all coding and claims submitted to third-party payers. In addition, the customer should note that laws, regulations, and coverage policies are complex and are updated frequently, and, therefore, the customer should check with its local carriers or intermediaries often and should consult with legal counsel or a financial, coding, or reimbursement specialist for any questions related to coding, billing, reimbursement, or any related issues. This material reproduces information for reference purposes only. It is not provided or authorized for marketing use.

References:

1. Social Security Administration website - https://www.ssa.gov/disability/professionals/bluebook/100.00-GrowthImpairment-Childhood.htm; Social Security Administration website - https://www.ssa.gov/ssi/text-other-ussi.htm.

2. Physician Prospective Payment-Final rule with Comment Period and Final CY2024 Payment Rates. CMS-1784-F: https://www.cms.gov/medicare/medicare-fee-service-payment/physicianfeesched/pfs-federal-regulation-notices/cms-1784-f

3. CMS_CY2024_Hospital Inpatient Prospective Payment-Final Rule Home Page CMS_1785-F: https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/fy-2024-ipps-final-rule-home-page

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at vascular.eifu.abbott or at manuals.eifu.abbott for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Abbott
3200 Lakeside Dr., Santa Clara, CA 95054 USA Tel: 1.800.227.9902
www.cardiovascular.abbott

MAT-1901119 v5.0 | Item approved for U.S. use only.

Abbott